1 -conjugated therapeutic proteins have been shown to exhibit clinical properties superior to those of their corresponding unmodified parent proteins (1) (2) (3) . Apparently, covalent binding of PEG to proteins produces steric interference, protecting conjugates from proteolysis and decreasing their rate of clearance from the circulation system via intracellular uptake and kidney filtration (2, 6, 7) .
To achieve these desired pharmacological features, several low molecular weight PEG chains or a single high molecular weight PEG must be linked to a protein (8) . However, this often drastically decreases the biological or pharmacological potency of the protein (4, 5) . Therefore, to maximize protection while minimizing reductions in bioactivity, PEGylation is usually applied to higher molecular weight proteins that are less likely to be inactivated by the procedure. However even such modification may lead to marked reduction in activity. For example, a currently used 40-kDa PEG-interferon-␣2a exhibits only 7% of the activity of the native cytokine, thus necessitating the administration of higher doses (9) . Furthermore, in contrast to its parent protein this 40-kDa PEG-interferon-␣2a does not readily penetrate all target tissues, as it is restricted to the blood and interstitial fluid (10) .
Several attempts to overcome these obstacles through reversible protein/peptide PEG-assisted delivery (e.g. by employing detachable PEG chains) have been reported (11) (12) (13) (14) (15) . They suffer, however, from major disadvantages including their dependence on enzymatic hydrolysis as the rate-determining step of PEG-parent molecule dissociation (11) (12) (13) , potentially making the behavior of the molecules unpredictable and their utilization impractical because of steric considerations and inappropriate enzyme availability. An additional disadvantage is the nonspecific PEGylation of undesired protein/peptide functional moieties (e.g. hydroxyls, imidazole, thiols (14) ), potentially causing post-PEGylation inter-and intramolecular reactions (14, 15) that could generate complex mixtures and immune-related risks.
In view of these issues, we tested a novel approach for designing PEG-peptide/protein conjugates from which PEG is released by spontaneous chemical hydrolysis. Reversible PEGprotein conjugation permits time-dependent reactivation of inactive PEGylated molecules. An appropriate conjugate would have to undergo slow and spontaneous hydrolysis under physiological conditions to yield the intact parent molecule (16 -19) . Our contributions are brought here in detail, using the antidiabetic peptide exendin-4 and human growth hormone (hGH) as in vivo and in vitro models, respectively.
EXPERIMENTAL PROCEDURES
Materials-Exendin-4 (HGEGTFTSDLSKQMEEEAVRLFIEWLKN-GGPSSGAPPPS-NH 2 ) and a non-lysine-containing synthetic peptide of 27 amino acids (AEISGQLSYVRDVNSWQHIWTNVSIEN) were synthesized by the solid phase method using a multiple peptide synthesizer, AMS 422 (Abimed Analyser Technik, GmbH). An Fmoc (N-(9-fluorenyl)methoxycarbonyl) strategy was employed throughout the peptide chain assembly. ␣-Lactalbumin, 5,5Ј-dithiobis(2-nitrobenzoic acid), reduced glutathione, and trinitrobenzene sulfonic acid were purchased from Sigma. PEG 40,000 -OSu (mPEG2-N-hydroxysuccinimide ester) was purchased from Shearwater (Huntsville, AL). All other materials used in this study were of analytical grade. A Centricon-50 ultrafiltration device for aqueous solutions was purchased from Millipore S.A.
Ultraviolet spectra were obtained by using a Beckman DU 7500 spectrophotometer in 1-cm path length UV cuvettes. Mass spectra were determined using MALDI-TOF and ESMS techniques (Bruker-ReflexReflectron model and VG-platform-II electrospray single quadropole mass spectrometer, Micro Mass, respectively).
HPLC analyses were performed using a Spectra-Physics SP8800 liquid chromatography system equipped with an Applied Biosystems 757 variable wavelength absorbance detector and a Spectra-SYSTEM * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ 1 The abbreviations used are: PEG, polyethylene glycol; hGH, human growth hormone; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight; ESMS, electrospray single quadropole mass spectrometer; MAL, maleimide; FMS, 9-hydroxymethyl-7-sulfofluorene-Nhydroxysuccinimide; OSu, hydroxysuccinimide ester; HPLC, high pressure liquid chromatography; TLC, thin layer chromatography; PBS, phosphate-buffered saline.
P2000 liquid chromatography system equipped with a Spectra-SYS-TEM AS100 autosampler and a Spectra-SYSTEM UV1000, all controlled by a ThermoQuest chromatography data system (ThermoQuest Inc., San Jose, CA). The column effluents were monitored by UV absorbance at 220 nm. Analytical reverse phase-HPLC was performed using a pre-packed Chromolith™ Performance RP-18e column (4.6 ϫ MAL-FMS-OSu-9-Hydroxymethyl-2-amino fluorene was synthesized with an 84% yield as described elsewhere (20) . Conditions were as follows: TLC, chloroform:methanol, 9:1 (v/v); R F ϭ 0.38; calculated ESMS ϭ 211.26 Da, and found ESMS for [MϩH] ϩ ϭ 212.10 Da. 3-Maleimidopropionic Anhydride-3-Maleimidopropionic acid (1 g, 5.9 mmol) and N,NЈ-dicyclohexylcarbodiimide (0.69 g, 2.95 mmol) were dissolved in 10 ml of N,N-dimethylformamide and incubated for 4 h. Dicyclohexylurea was filtered out, and the anhydride formed was kept at 4°C.
9-Hydroxymethyl-2-amino fluorene (0.4 g, 1.9 mmol) and NaHCO 3 (0.74 g, 8.85 mmol) were dissolved in water and 3-maleimidopropionic anhydride in N,N-dimethylformamide (12 ml, 2.95 mmol) was added. The reaction mixture was stirred for 40 min, and product formation was monitored by analytical HPLC on a Chromolith column (R t ϭ 4.46 min, 10 -100% solution B in 10 min, 3 ml/min). The crude product was purified using preparative HPLC (RP-18 column, 10 -100% acetonitril: water (75:25; v/v), 60 min, 12 ml/min). The yield was 57%, 1.08 mmol, 0.39 g; calculated ESMS ϭ 362.38 Da, and found ESMS ϭ 362.42 Da.
Pyridine (0.167 ml, 2 mmol) was added dropwise to a stirred solution of 9-hydroxymethyl-2-(amino-3-maleimidopropionate)fluorene (0.37g, 1.02 mmol) and triphosgene (0.425 g, 1.43 mmol) in dry tetrahydrofuran (10 ml). After 20 min the precipitated pyridine hydrochloride salt was filtered out, and the tetrahydrofuran was removed by vacuum. The oil obtained was dissolved in 10 ml of dry tetrahydrofuran with N-hydroxysuccinimide (0.61g, 5.3 mmol). Pyridine (0.26 ml, 3.2 mmol) was then added, and the solution was stirred for 20 min. Some additional precipitated pyridine hydrochloride salt was filtered out, and the tetrahydrofuran was removed by vacuum. The oil obtained was dissolved in chloroform (100 ml) and washed with an aqueous NaHCO 3 solution (0.5 N, 3 ϫ 50 ml), HCl (0.1 N, 3 ϫ 50 ml), water (2 ϫ 50 ml), and brine. The chloroform was removed by vacuum, and the product was desiccated. Conditions were as follows: yield was 89%, 0.9 mmol, 0.45 g; HPLC (Chromolith column) R t ϭ 5.7 min (10 -100% solution B in 10 min, 3 ml/min). Calculated ESMS ϭ 503 Da, found ESMS for [MϩNa] ϩ ϭ 526.38 Da, and found ESMS for [MϩK] ϩ ϭ 542.30 Da.
9-Hydroxymethyl-2-(amino-3-maleimidopropionate)-7-sulfofluorene
N-Hydroxysuccinimide-To a solution of 9-hydroxymethyl-2-(amino-3-maleimidopropionate)-fluorene N-hydroxysuccinimide (0.2 mmol, 0.1 g) in trifluoroacetic acid (10 ml), chlorosulfonic acid (0.5 ml) was added. After 15 min, cold ether (90 ml) was added, and the precipitated product was washed three times with ether and desiccated. Conditions were as follows: yield: 95%, 0.11 g, 0.19 mmol; HPLC (Chromolith column) R t ϭ 2.65 min (10 -100% solution B in 10 min, 3 ml/min). ϩ ϭ 606.47 Da. PEG 40,000 -SH-PEG 40,000 -OSu was dissolved at a concentration of 40 mg/ml in an aqueous solution of cystamine-di-HCl (1 M) and brought to pH 8.5 with NaHCO 3 . Reaction was carried out for 2 h at 25°C. The product thus obtained was dialyzed overnight against 0.1 M NaHCO 3 , treated with 30 mM dithiothreitol (25°C, 1 h), and redialyzed against 0.01 M HCl. PEG 40,000 -SH was obtained with a 93% yield. It contained 1 mol sulfhydryl moiety per mol of PEG 40,000 as determined with 5,5Ј-dithiobis(2-nitrobenzoic acid) in the presence of ascorbate.
Preparation of PEG 5000 -2-Sulfo-9-fluorenylmethoxycarbonyl N-Hydroxysuccinimide-MAL-FMS-OSu (1.8 mg, 3 mol) was added to a solution of PEG 5000 -SH (15 mg, ϳ3 mol) in phosphate-buffered saline (PBS) (0.5 ml, pH 7.4), and the reaction solution was stirred for 30 min. The product PEG 5000 -FMS-OSu was purified by HPLC on an RP-4 column and lyophilized.
PEG 5000 -FMS-Exendin-4 -PEG 5000 -FMS-OSu (2.3 mg, ϳ0.42 mol) was added to a solution of exendin-4 (1.6 mg, 0.4 mol) in PBS (0.5 ml, pH 8), and the reaction solution was stirred for 2 h. The product PEG 5000 -FMS-exendin-4 was purified by HPLC on an RP-4 column and lyophilized.
Preparation of PEG 40,000 -FMS-Exendin-4 -To a stirred solution of exendin-4 (1 mg in 1.0 ml of 0.1 M phosphate buffer, 2 mM ascorbate, pH 7.2, 0.239 mM) was added 280 g of MAL-FMS-OSu (28 l from a fresh solution of MAL-FMS-OSu in N,N-dimethylformamide, 10 mg/ml, 2.0 molar excess over the peptide). After 7 min, solid PEG 40,000 -SH was added to a final concentration of 0.5 mM (2.1 molar excess over the peptide). The reaction was carried out for 1 h, dialyzed overnight against H 2 O, and then further filtered through Centricon with a molecular mass cutoff of 50 kDa to remove any residual exendin-4 or MAL-FMS-exendin-4 that had not linked to PEG 40,000 -SH. The concentration of the conjugate was determined by amino acid analysis according to the content of aspartic acid (two residues), alanine (two residues) and valine (one residue), or calculated from the absorbance of the conjugate at 280 nm. The calculated extinction coefficient at 280 nm was 26,940 Ϯ 100, a value that is the additive absorbance of exendin-4 (⑀ 280 ϭ 5740) and PEG 40 FMS-exendin-4. MAL-FMS-OSu (280 g) was added to a solution of hGH (4.5 mg, 0.225 mol) in 0.5 ml of PBS, pH 7.4. After 10 min PEG 40,000 -SH (10 mg) was added, and the reaction mixture was stirred for 1 h and dialyzed overnight against water. An hGH displacement assay was performed as described elsewhere (21) .
Glucose-lowering Assay of PEG 40,000 -FMS-Exendin-4 -Three groups of CD1 mice (n ϭ 6 per group) subcutaneously received saline, native exendin-4 (4 g/mouse), or PEG 40,000 -FMS-exendin-4 (4 g of peptide/ mouse). Circulating glucose levels were measured with a glucose analyzer (Beckman Instruments) by the glucose oxidase method. Blood samples for the blood glucose analyses were taken from the tail veins. The level of glucose in normal healthy CD1-mice was 140 Ϯ 7 mg/dl (7.77 mM).
Glucose-lowering Assay of Released Exendin-4 -PEG 40,000 -FMS-exendin-4 (0.36 mg containing 30 g of exendin-4) was incubated for 24 h at pH 8.5, 37°C. The released peptide was separated from the PEG 40,000 -sulfodibezofulvene using HPLC on a Chromolith column (10 -100% solution B in 10 min, 3 ml/min), and the peptide solution was lyophilized. The peptide concentration was determined by its absorbance at 220 nm. Native exendin-4 and the released exendin-4 were dissolved in saline and administered subcutaneously at identical doses to five groups of CD1 mice (n ϭ 3 per group). Circulating glucose levels were then determined as described above.
RESULTS
We have designed, synthesized, and characterized MAL-FMS-OSu, Fig. 1A ). This is a water-soluble heterobifunctional reagent consisting of a sulfonated fluorenyloxycarbonyl N-hydroxysuccinimide ester that reacts with peptide and protein amino groups. A maleimide group was attached to the fluorenyl backbone to enable coupling to sulfhydryl-containing PEG-SH (Fig. 1B) . At 320 nm, where peptides or proteins absorb negli-
TABLE I Structures and half-lives of PEG-FMS conjugates
a Rate of hydrolysis was followed by trinitrobenzene sulfonic acid assay. b k is the slope constant derived from the plot of ln(PEG-FMS conjugate) against time (h). c t 1/2 was determined from the formula t 1/2 ϭ ln 2/k. gibly, MAL-FMS-OSu (either free or covalently bound to proteins) absorbs with a molar extinction coefficient (⑀ 320 ) of 16,100 Ϯ 150 mol Ϫ1 cm Ϫ1 . Fig. 2 , samples of ␣-lactalbumin (1 mg/ml) were modified with increasing concentrations of MAL-FMSOSu in 0.1 M PBS, pH 7.2, for 30 min at 25°C. That is, under experimental conditions where the maleimide-alkylating capacity of the spacer remains nonmodified (see the next paragraph). About 1 mol of MAL-FMS was incorporated into ␣-lactalbumin per 2.1 mol of reagent added, up to a 14 molar excess over the protein (Fig. 2) .
Degree of MAL-FMS Incorporation as a Function of the Spacer Added-In

Stability of the MAL Function in Aqueous Solutions-Fig. 3 demonstrates the potency of the reaction of MAL-FMS-OSu
with reduced glutathione as a function of time at different pH values. MAL-FMS-OSu was found fully stable at pH 4 -6 over a period of a day or two, and at pH 7.2 it is stable over a period of several hours. At pH 8.5 the maleimido moiety is destroyed at an accelerated rate (t1 ⁄2 ϭ 2.7 Ϯ 0.3 h, Fig. 3) .
Two possible pathways for the related PEGylation of target peptides, proteins, and small molecules are suggested (Fig. 1B) . One involves attaching MAL-FMS-OSu to the amine component of the target and then substituting PEG-SH for the maleimide moiety. The second option involves preparing PEG-FMS-OSu, which then reacts with the amine component of the target (Fig. 1B) . This pathway is suitable for sulfhydryl-or disulfide-containing peptides and proteins.
Rate of Hydrolysis of PEG-FMS Conjugates-Four PEG-FMS conjugates and one MAL-FMS conjugate were prepared using the described pathways (see Table I and "Experimental Procedures"). The hydrolysis rates and reaction orders of PEG 5000 -FMS-4-nitro-phenethylamine, PEG 5000 -FMS-exendin-4, PEG 40,000 -FMS-exendin-4, and PEG 40,000 -FMS-hGH were evaluated at pH 8.5, 37°C (Table I ). The hydrolysis rate at pH 8.5 is equivalent to the hydrolysis rate in serum as shown previously (16 -19) . The release of 4-nitro-phenethylamine, exendin-4, and hGH was monitored by reverse phase-HPLC and was determined to be a first order reaction (Table I and Figs. 4 and 5). As shown (Fig. 4 and Table I), the peptides and protein were released from the conjugates in a slow homogenous fashion, with t1 ⁄2 of 9.4, 13.8, 11.9, and 11.8 h. Exendin-4 was fully released from the PEG 40,000 conjugate after 48 h of incubation.
Demonstrating the Validity of Reversible PEGylation with hGH and Exendin-4 -In vitro, PEG 40
,000 -FMS-hGH exhibits no receptor binding affinity. Upon incubation, recognition of the released hGH by the native hGH receptor was preserved (Fig. 5) .
Exendin-4 is an insulinotropic glucagon-like peptide-1 agonist that associates with ␤-pancreatic cells, elevates endogenous cAMP levels, enhances secretion of insulin, and lowers circulating glucose levels (22) (23) (24) (25) . A profound pharmacological advantage of this glucagon-like peptide-1 agonist is that (following administration at any dosage) the circulating blood glucose level never falls below a threshold that in non-diabetic healthy CD1 mice is 74 Ϯ 7 mg/dl (26) . Fig. 6 shows the glucose-lowering profile of subcutaneously administered native exendin-4 and of PEG 40,000 -FMS-exendin-4 at a dose of 4 g of peptide/mouse relative to a saline-treated group of mice. With the native peptide, blood glucose level declined 26 -28% (from 140 to 104 -101 mg/dl) with the largest percent change in blood glucose level occurring 0.5-1 h after administration. Glucose concentrations then returned to their initial levels with a t1 ⁄2 of   FIG. 4 . The rate of hydrolysis of PEG-FMS conjugates upon incubation at pH 8.5, 37°C is shown in A. Solutions of PEG 40,000 -FMS-exendin-4 (right, E), PEG 5000 -FMS-exendin-4 (left, E), and PEG 5000 -FMS-4-nitro-phenethyl amine (left, Ⅺ) were incubated in PBS at pH 8.5, 37°C. At the indicated time points, aliquots (50 l) were analyzed using HPLC on an RP-4 column. Results are expressed as percent of the maximal peak area of released exendin-4 and 4-nitrophenethylamine as a function of time. B, the concentration of PEG 40,000 -FMS-exendin-4 (E) and PEG 40,000 -FMS-hGH (Ⅺ) was determined for each time point by HPLC. The linear plot obtained indicates that the rate of hydrolysis is of first order reaction. The half-life time of the conjugates was calculated from t1 ⁄2 ϭ ln 2/k, when k is the slope of the linear plot (h Ϫ1 ).
3.7 Ϯ 0.3 h. Following the subcutaneous administration of PEG 40,000 -FMS-exendin-4, the decrease in blood glucose level took place at a more moderate rate. Circulating glucose reached its lowest concentration 8 -12 h after administration (92 mg/dl, 33%). Stable, low circulating glucose concentrations were then maintained for a further 12 h. Return to initial glucose levels took place with a t1 ⁄2 of 30 Ϯ 2 h, which is 7.5 times longer than that obtained by the same dose of the native hormone.
Irreversibly conjugated PEG 40,000 -exendin-4 has only Յ1% of the activity of native exendin-4 (IC 50 ϭ 250 Ϯ 30 pmol/mouse versus IC 50 ϭ 2.5 Ϯ 0.24 pmol/mouse for the native exendin-4, not shown). Fig. 7 shows the glucose-lowering pattern of exendin-4 released from the PEG 40,000 -FMS-exendin-4 conjugate by incubation at pH 8.5, 37°C for 24 h. The glucose-lowering pattern of the released exendin-4 was indistinguishable from that obtained by the native peptide; both reduced blood glucose levels by 30 and 50% 1 h after subcutaneous administration of 0.1 and 1 g of peptide/mouse, respectively. DISCUSSION PEGylation's previously mentioned side effect of drastically decreasing drug bioactivity has meant that only a limited number of such conjugates have found clinical application (5) . This happens despite the profound advantages that steric protection confers in elongating the lifetimes of the drugs in vivo, protecting them from proteolysis and shielding them from the immune system (4 -8) . Theoretically, decreased bioactivity can be overcome by linking the PEG chains via a chemical bond sensitive to mild alkaline and/or acid hydrolysis or enzymatically able to be cleaved by serum proteases or esterases. Obviously, an inconsistent rate of hydrolysis would render such an approach impractical. A prerequisite condition is therefore that the hydrolysis of the PEG chains from the conjugate takes place at a slow rate and in a homogenous fashion under the strictly homeostatic pH and temperature conditions of the mammalian circulatory system (27) .
Biological Potency of Exendin-4 that Was Released from PEG 40,000 -FMS-Exendin-4 Conjugate-
Previously, we prepared FMS-OSu (17-19) as a reversible protein modifier. Protein-linked FMS moieties undergo slow and spontaneous hydrolysis under physiological conditions, generating the unmodified parent molecule. Hydrolysis of FMS-protein conjugates at 37°C in normal human serum, in aqueous buffers of pH 8.5, or in the circulatory system in vivo takes place with a t1 ⁄2 of 5-7 h. Using the FMS moiety as the scaffold for the suggested reversible PEGylation technology enables the hydrolysis rates of various PEG-FMS-protein conjugates to be predicted. The t1 ⁄2 for the hydrolysis of modified FIG. 5 . Time course of reactivation of PEG 40,000 -FMS-hGH upon incubation at pH 8.5, 37°C. PEG 40,000 -FMS-hGH (1 mg/ml) was incubated in 0.1 M phosphate buffer, 0.6% bovine serum albumin, and 2 mM NaN 3 at 37°C. Aliquots were withdrawn at the indicated time points and analyzed for their potencies in displacing 125 I-hGH from enriched hGH receptor preparation extracted from rabbit liver plasma membranes. Native hGH displaces 125 I-hGH in this assay half-maximally at a concentration of 0.3 Ϯ 0.03 nM. An hGH derivative exhibiting half-maximal displacement in this assay at a concentration of 3.0 Ϯ 0.3 nM is considered to have 10% of the binding potency of the native receptor. The rate of release of hGH from PEG 40 -FMS-hGH upon incubation at pH 8.5, 37°C is shown in the inset. PEG 40,000 FMS-hGH (1 mg of protein) was incubated as described above. At the indicated time points, 0.1-ml aliquots were withdrawn and subjected to analytical HPLC analysis.
FIG. 6.
Glucose-lowering patterns of native exendin-4 and PEG 40,000 -FMS-exendin-4 following a single subcutaneous administration to CD1-mice. Three groups of CD1 mice (n ϭ 6 per group) underwent one subcutaneous administration of saline, native exendin-4 (Ⅺ, 4 g/mouse), or PEG 40,000 -FMS-exendin-4 (f, 4 g of peptide/mouse). Circulating glucose levels were then monitored. Results are expressed as percent decrease in plasma glucose concentration in the groups treated with exendin-4 or PEG 40,000 -FMS-exendin-4 relative to that found in the saline-treated group measured at the same time point during the day.
FIG. 7.
Glucose-lowering patterns of exendin-4 released from PEG 40,000 -FMS-exendin-4. Five groups of CD1 mice (n ϭ 3 per group) underwent one subcutaneous administration of saline, native exendin-4, or released exendin-4 (1 and 0.1 g of peptide/mouse, respectively). Circulating glucose levels were then determined. Results are expressed as plasma glucose levels (mg/dl) measured following subcutaneous administration. f, native exendin-4 (0.1 g); Ⅺ, released exendin-4 (0.1 g); q, native exendin-4 (1 g); E, released exendin-4 (1 g).
small molecules and PEG-conjugated polypeptides and proteins falls within a relatively narrow range of 8 -14 h (Table I) . The constant hydrolysis rate for PEG-FMS-protein conjugates is caused by the ␤-elimination reaction, which occurs at position 9 of the fluorenyl moiety (Fig. 1B) and is solely dependent on the pH of the surrounding medium. Thus, in contrast to what occurs in studies based on enzymatic hydrolytic bond cleavage, similar PEG-FMS hydrolysis rates are expected from all conjugates regardless of the identity of the protein/peptide moiety conjugated. Using the present approach one can further control the hydrolysis rate by substituting the fluorenyl moiety with electron-withdrawing or electron-inducing groups that increase or decrease, respectively, the hydrolysis rate. The number of PEG-FMS chains attached to a drug should also affect the rate at which the native drug is released.
Exendin-4 contains one His N ␣ amino function and two Lys N ⑀ amino groups, enabling modification at these three positions. Indeed, N-terminal amino acid sequencing revealed that, although the PEG 40,000 -FMS-exendin-4 product eluted as a single peak on HPLC, it was actually a mixture containing primarily the N ␣ -modified hormone. Similarly, hGH contains several amino functions that may be conjugated. However, in view of the reversibility of the PEGylation reaction, which regenerate the native peptide and protein hormones, this point deserves only minor consideration.
Calculations based on the hydrolysis rates of FMS-exendin-4 and PEG 40,000 -FMS-exendin-4 at 37°C in normal sera and PBS, pH 8.5, respectively, revealed that ϳ4% of exendin-4 is released from the conjugate each hour in vivo (19) . We further hypothesized that this release rate if combined with prolonged maintenance of the conjugate in the circulatory system prior to exendin-4 hydrolysis should yield a long lasting glucose-lowering signal in mice, as indeed is found following a single subcutaneous administration of PEG 40,000 -FMS-exendin-4 conjugate (Fig. 6) .
It should be noted that the covalently linked exendin-4 is fully active following its release from PEG 40,000 -FMS-exendin-4 by incubation (Fig. 7) , suggesting that the conjugation per se does not lead to irreversible modification and/or denaturation of the peptide.
The sulfonated fulvene moiety is not toxic as previously shown (19) . High molecular weight PEG is known to be safe in terms of toxicity and immunogenicity and is widely used in the food, cosmetic, and pharmaceutical industries (28, 29) .
In summary a conceptual approach termed "reversible PEGylation" was implemented here with low molecular weight polypeptides and proteins. This novel approach enables the desirable pharmacological features associated with PEGylation to be conferred on low molecular weight peptide and protein drugs that would otherwise have been fully or partially inactivated by this technique. A pharmacologically "silent" conjugate that is "trapped" in the circulatory system releases the covalently linked parent peptide or protein with a desirable pharmacokinetic profile. This new development is expected to extend the lifetime, bioavailability, and efficacy of existing peptide drugs and to extend the same in peptide drug candidates that may yet be discovered by genomics and proteomics.
